Ying‐Jun Chang
YOU?
Author Swipe
View article: Cerebrospinal fluid profile associated with the incidence and outcomes of patients with chronic graft-versus-host disease after haploidentical hematopoietic stem cell transplantation
Cerebrospinal fluid profile associated with the incidence and outcomes of patients with chronic graft-versus-host disease after haploidentical hematopoietic stem cell transplantation Open
Chronic graft-versus-host disease (cGVHD) is a major complication of haploidentical hematopoietic stem cell transplantation (haplo-HSCT). In our previous studies, we speculated that cGVHD might be closely related to immune-mediated encepha…
View article: Vennetoclax combined with decitabine, cytarabine, aclacinomycin and granulocyte colony-stimulating factor as induction regimen achieved high response rate in newly diagnosed adverse risk Acute Myeloid Leukemia
Vennetoclax combined with decitabine, cytarabine, aclacinomycin and granulocyte colony-stimulating factor as induction regimen achieved high response rate in newly diagnosed adverse risk Acute Myeloid Leukemia Open
Background With the identification of increasing molecular markers, acute myeloid leukemia (AML) patients in the adverse risk group constitute a growing proportion of the overall AML population according to the 2022 European LeukemiaNet ge…
View article: Novel insights from the largest cohort to date: Elucidating risk factors, clinical outcomes, and prognostic predictors in autoimmune hemolytic anemia following allogeneic hematopoietic stem cell transplantation
Novel insights from the largest cohort to date: Elucidating risk factors, clinical outcomes, and prognostic predictors in autoimmune hemolytic anemia following allogeneic hematopoietic stem cell transplantation Open
Introduction Autoimmune hemolytic anemia (AIHA) is a rare yet serious hematologic disorder, defined as hemolytic anemia characterized by the destruction of red blood cells (RBCs) mediated by autoantibodies targeting antigens on the RBC sur…
View article: Development and prospective validation of a prognostic model for diffuse alveolar hemorrhage after allogeneic hematopoietic stem cell transplantation
Development and prospective validation of a prognostic model for diffuse alveolar hemorrhage after allogeneic hematopoietic stem cell transplantation Open
Introduction Diffuse alveolar hemorrhage (DAH) is a life-threatening pulmonary complication that can occur after allogeneic hematopoietic stem cell transplantation (allo-HSCT) without an explicit etiology, and there is no standard treatmen…
View article: Multi‐omics integration analysis identifies INPP4B as a T‐cell‐specific activation suppressor
Multi‐omics integration analysis identifies INPP4B as a T‐cell‐specific activation suppressor Open
Background Naïve T cells are maintained in a quiescent state prior to activation. As inappropriate T‐cell activation can lead to impaired immune tolerance and autoimmune diseases, the transition from quiescence to activation must be under …
View article: A New Risk Score System for Early Warning Gastrointestinal Graft-Versus-Host Disease Based on the Immune Function of Mucosal-Associated Invariant T Cells
A New Risk Score System for Early Warning Gastrointestinal Graft-Versus-Host Disease Based on the Immune Function of Mucosal-Associated Invariant T Cells Open
Gastrointestinal acute graft-versus-host disease (GI aGVHD) remains one of the major clinical challenges following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Early identification and intervention are critical to improv…
View article: Prognostic value of <scp><i>CEBPA</i> bZIP</scp> signatures in cytogenetically normal acute myeloid leukaemia
Prognostic value of <span><i>CEBPA</i> bZIP</span> signatures in cytogenetically normal acute myeloid leukaemia Open
Summary Recent studies revealed that CEBPA with basic leucine zipper (bZIP) in‐frame mutation ( CEBPA bZIP‐inf ) is the bona fide entity with a favourable prognosis in acute myeloid leukaemia. However, the mechanism by which the bZIP signa…
View article: Clinical Effects of RUNX1 Mutations on the Outcomes of Patients with Acute Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem-Cell Transplantation
Clinical Effects of RUNX1 Mutations on the Outcomes of Patients with Acute Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem-Cell Transplantation Open
It is reported that AML with RUNX1 mutations is associated with poorer response to conventional chemotherapy, lower rates of complete remission (CR), leukemia-free survival (LFS), and overall survival (OS). We aimed to evaluate the prognos…
View article: Overexpressing natural killer group 2 member A drives natural killer cell exhaustion in relapsed acute myeloid leukemia
Overexpressing natural killer group 2 member A drives natural killer cell exhaustion in relapsed acute myeloid leukemia Open
Acute myeloid leukemia (AML) relapse is associated with poor prognosis. While natural killer (NK) cell therapy can induce leukemia remission, infused NK cells are prone to exhaustion. Elucidating the molecular mechanisms driving NK cell ex…
View article: Lack of Evidence Supporting a Significant Benefit of Pre-Transplant Consolidation Therapy in AML CR2 Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Lack of Evidence Supporting a Significant Benefit of Pre-Transplant Consolidation Therapy in AML CR2 Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Open
Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is a well-established curative treatment option for acute myeloid leukemia (AML) in second complete remission (CR2). However, whether the addition of consolidation chemo…
View article: The effect of TIGIT and PD1 expression on T cell function and prognosis in adult patients with acute myeloid leukemia at diagnosis
The effect of TIGIT and PD1 expression on T cell function and prognosis in adult patients with acute myeloid leukemia at diagnosis Open
T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) is a recently-identified immune checkpoint molecule, and no study ever explores the prognostic significance of TIGIT on bone marrow T cells of newly-diagnosed acute myeloid …
View article: Stem cell transplantation indications for patients with acute leukemia determined by measurable residual disease: what we know and what we do not know
Stem cell transplantation indications for patients with acute leukemia determined by measurable residual disease: what we know and what we do not know Open
Acute leukemia (AL), which includes acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), is a hematological malignancy characterized by the uncontrolled proliferation of immature myeloid or lymphoid cells. Allogeneic stem c…
View article: Monitoring the <scp> <i>KMT2A</i> </scp> gene post‐chemotherapy independently predicts the relapse and survival risk after allogeneic haematopoietic stem cell transplantation
Monitoring the <span> <i>KMT2A</i> </span> gene post‐chemotherapy independently predicts the relapse and survival risk after allogeneic haematopoietic stem cell transplantation Open
Summary This study evaluated the kinetics of KMT2A ‐r during chemotherapy and its impact on allogeneic haematopoietic stem cell transplantation (allo‐HSCT) outcomes. KMT2A‐r was assessed post‐induction (MRD1), after the first (MRD2) and se…
View article: Venetoclax and azacitidine compared with intensive chemotherapy for adverse-risk acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation in first complete remission: A multicenter study of TROPHY group
Venetoclax and azacitidine compared with intensive chemotherapy for adverse-risk acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation in first complete remission: A multicenter study of TROPHY group Open
Our results suggest that IC remains the cornerstone of therapy, whereas VEN-AZA may also be used in younger patients and medically fit patients with adverse-risk AML who are receiving allo-HSCT in CR1.
View article: Characterizing the Heterogeneity of MAIT Cells in Grafts Using Single-Cell RNA Sequencing to Assist in the Precise Diagnosis of Gastrointestinal GVHD
Characterizing the Heterogeneity of MAIT Cells in Grafts Using Single-Cell RNA Sequencing to Assist in the Precise Diagnosis of Gastrointestinal GVHD Open
Granulocyte colony-stimulating factor (G-CSF) enhances acute graft-versus-host disease (aGVHD) prophylaxis in allogeneic hematopoietic stem cell transplantation (allo-HSCT) by inducing T cell tolerance and altering graft cell composition. …
View article: AIM2 Mediates Immune Evasion of Acute Myeloid Leukemia Cells
AIM2 Mediates Immune Evasion of Acute Myeloid Leukemia Cells Open
Background Acute myeloid leukemia (AML) is a severe hematologic malignancy with high frequency of recurrence but low sensitivity to current immunotherapy. Understanding the molecular mechanism and discovery of new targets for AML immunothe…
View article: Exploring the Prognostic Significance of Graft CD161-Expressing T Cells in Allo-HSCT
Exploring the Prognostic Significance of Graft CD161-Expressing T Cells in Allo-HSCT Open
Background: CD161 (NKR-P1A) is known for its role in inhibiting natural killer (NK) cell-mediated tumor cytotoxicity, with CLEC2D (also known as lectin-like transcript 1, LLT1) identified as its ligand. Unlike the widely studied T cell inh…
View article: Myelodysplastic Syndrome Stem Cells Evaluated By Multiparameter Flow Cytometry Are Associated with Posttreatment Relapse: A Prospective Study
Myelodysplastic Syndrome Stem Cells Evaluated By Multiparameter Flow Cytometry Are Associated with Posttreatment Relapse: A Prospective Study Open
Background: We previously showed that leukemia stem cell (LSC)-based measurable residual disease (MRD) assay (Leukemia,2016;30:439-446), mainly including a cocktail panel of CD7, CD11b, CD22, CD56, CD366, and CD371 on CD34+CD38- cells, is …
View article: Sintilimab plus decitabine for higher-risk treatment-naïve myelodysplastic syndromes: efficacy, safety, and biomarker analysis of a phase II, single-arm trial
Sintilimab plus decitabine for higher-risk treatment-naïve myelodysplastic syndromes: efficacy, safety, and biomarker analysis of a phase II, single-arm trial Open
Background Immunotherapy combined with azacitidine was feasible in higher-risk myelodysplastic syndromes (MDSs) with limited sample size of treatment-naïve patients, while the optimization of treatment strategies, including the optimal imm…
View article: Venetoclax and azacitidine compared with intensive chemotherapy for adverse-risk acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation in first complete remission: a multicenter study of TROPHY group.
Venetoclax and azacitidine compared with intensive chemotherapy for adverse-risk acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation in first complete remission: a multicenter study of TROPHY group. Open
It was commonly accepted that adverse-risk acute myeloid leukemia patients should receive allogeneic hematopoietic stem cell transplantation (allo-HSCT) in first complete remission (CR1). In this multicenter study, we aimed to compare the …
View article: Safety and efficacy of baricitinib in steroid‐resistant or relapsed immune thrombocytopenia: An open‐label pilot study
Safety and efficacy of baricitinib in steroid‐resistant or relapsed immune thrombocytopenia: An open‐label pilot study Open
Patients with steroid‐resistant or relapsed immune thrombocytopenia (ITP) suffer increased bleeding risk and impaired quality of life. Baricitinib, an oral Janus‐associated kinases (JAK) inhibitor, could alleviate both innate and adaptive …
View article: Risk factors for positive post-transplantation measurable residual disease in patients with acute lymphoblastic leukemia
Risk factors for positive post-transplantation measurable residual disease in patients with acute lymphoblastic leukemia Open
Background: The level of measurable residual disease (MRD) before and after transplantation is related to inferior transplant outcomes, and post-hematopoietic stem cell transplantation measurable residual disease (post-HSCT MRD) has higher…
View article: Cytology or Multiparameter Flow Cytometry Positivity in the Cerebrospinal Fluid Before Transplantation is Predictive of Poor Outcomes After Allotransplantation in Acute Myeloid Leukemia Patients
Cytology or Multiparameter Flow Cytometry Positivity in the Cerebrospinal Fluid Before Transplantation is Predictive of Poor Outcomes After Allotransplantation in Acute Myeloid Leukemia Patients Open
Introduction Central nervous system leukemia (CNSL) remains a serious complication in patients with acute myeloid leukemia (AML) and an ambiguous prognostic factor for those receiving allo‐geneic hematopoiesis stem cell transplantation (al…
View article: Desensitization Strategies for Donor-Specific Antibodies in HLA-Mismatched Stem Cell Transplantation Recipients: What We Know and What We Do Not Know
Desensitization Strategies for Donor-Specific Antibodies in HLA-Mismatched Stem Cell Transplantation Recipients: What We Know and What We Do Not Know Open
In human leukocyte antigen (HLA)-mismatched allogeneic stem cell transplantation settings, donor-specific anti-HLA antibodies (DSAs) can independently lead to graft failure, including both primary graft rejection and primary poor graft fun…